Zuclomifene - Veru Healthcare

Drug Profile

Zuclomifene - Veru Healthcare

Alternative Names: APP 944

Latest Information Update: 19 Jun 2017

Price : $50

At a glance

  • Originator Aspen Park Pharmaceuticals
  • Developer Veru Healthcare
  • Class Antineoplastics; Infertility therapies
  • Mechanism of Action Estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hot flashes

Most Recent Events

  • 23 Jun 2017 Veru Healthcare plans to file an IND application with the US FDA for Hot flashes (in patients with advanced prostate cancer undergoing treatment with hormonal therapy) in 2017 (Veru Healthcare pipeline, June 2017)
  • 23 Jun 2017 Veru Healthcare plans a phase II trial for Hot flashes (In patients with advanced prostate cancer undergoing treatment with hormonal therapy) in USA in late 2017 (Veru Healthcare pipeline, June 2017)
  • 27 Jan 2016 Preclinical trials in Hot flashes in USA (PO) before January 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top